<DOC>
	<DOCNO>NCT00269035</DOCNO>
	<brief_summary>This study conduct 2 group schizophrenic patient : group 1 relationship dopaminergic D2 receptor occupancy ( D2 RO ) serotoninergic 5HT2A receptor occupancy stable plasma concentration ( Cp ) SB-773812 investigate use SPECT scan 15 chronic schizophrenic patient open- label design . In group 2 80 patient receive SB-773812 Risperidone 6 week obtain least 10 patient show clinical improvement SB-773812 . The relationship D2 RO , measure steady state chronic dosing Cmax ( 6+/-2 h ) Ctrough ( 24+/-4 h ) , PK steady state repeat dos , efficacy readout investigate . The SB-773812 dose administer select high dose proven safe well tolerate previous study .</brief_summary>
	<brief_title>SPECT Study With SB-773812 In Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Inclusion criterion : schizophrenic patient diagnose DSM IV criterion . In group 2 , subject schizophrenia schizophreniform disorder show moderate disease exacerbation , PANSS score &gt; 65 score PANSS positive scale ( PANSSP ) =25 . Women childbearing potential must agree acceptable method birth control . Exclusion criterion : Subject show severe exacerbation , extreme instability , high risk suicide serious violent behaviour . Any clinically laboratory significant abnormality . Subjects receive radiation dose activity 10 mSv 3 year period . Subjects organic brain disease history severe head trauma . Heart pacemaker , metallic prosthesis metallic body implant . Significant head deformity . Smokers associate COPD . History presence clinically significant gastrointestinal , hepatic renal disease . History cholecystectomy biliary tract disease . Positive HBV , HCV HIV . Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>SB-773812</keyword>
	<keyword>SPECT</keyword>
	<keyword>D2 RO</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>schizophrenic patient</keyword>
	<keyword>5HT2A RO</keyword>
</DOC>